BioRestorative Therapies (NASDAQ:BRTX) Releases Earnings Results, Beats Estimates By $0.22 EPS

BioRestorative Therapies (NASDAQ:BRTX) posted its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.22, Zacks reports. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.30 million. BioRestorative Therapies had a negative return on equity of 93.89% and a negative net margin of 2,697.08%.

BioRestorative Therapies Price Performance

Shares of BioRestorative Therapies stock traded down $0.02 during trading on Thursday, hitting $1.53. 27,286 shares of the company’s stock traded hands, compared to its average volume of 768,548. BioRestorative Therapies has a twelve month low of $1.03 and a twelve month high of $3.67. The company has a market cap of $10.55 million, a PE ratio of -1.03 and a beta of 63.40. The firm’s fifty day moving average price is $1.63 and its 200 day moving average price is $1.60.

Analyst Upgrades and Downgrades

Separately, Roth Mkm raised their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.